Summary
The pharmacokinetics of pengitoxin has been studied in 28 healthy subjects after intravenous and oral administration. The mean plasma concentration 24 h after 0.5 mg i.v. was 5.2 ng · ml−1. Following an open two-compartment model a mean elimination half-life of 60.5 h (24.9 to 103.5 h) and a mean volume of distribution (Vdarea) of 66.91 (31.8 to 109.61) were calculated. Absorption calculated by comparison of the AUC0-∞-values amounted to 99%. Within 4 days, 16.7% (11.7 to 21.1%) or 27.8% (18.4 to 33.7%) (0.5 mg i.v. or 1.2 mg p.o.) was excreted in urine. After pengitoxin 0.5 mg i.v. total body clearance and renal clearance were 13.3 ml · min−1 (7.0 to 18.6 ml · min−1) and 3.0 ml · min−1 (1.9 to 3.9 ml · min−1) respectively. The elimination half-life of pengitoxin is longer than that of digoxin and distinctly shorter than that of digitoxin, whilst its distribution volume and clearance are closer to those of digitoxin than of digoxin.
Similar content being viewed by others
References
Belz GG, Nübling H (1975) Half life in plasma following repetitive application ofβ-acetyl-digoxin in man. Klin Wochenschr 53:543–544
Blumenthal HP (1979) Pharmacokinetic models for digitoxin. In: Greeff K, Rietbrock N (eds) Digitoxin. Schattauer-Verlag, Stuttgart, p 52–60
Fiehring H, Sundermann A, Knappe J (1983) Penta-acetyl-gitoxin — ein neues Herzglykosid. Dtsch Gesundheitswes 18:1334–1338
Greenblatt DJ, Koch-Weser J (1975) Clinical pharmacokinetics. N Engl J Med 293:702–705
Hartley HO (1948) The estimation of non-linear parameters by internal least squares. Biometrika 35:32–45
Haustein KO (1978) Measurement of plasma glycoside level following pengitoxin administration. Eur J Clin Pharmacol 13:389–391
Haustein KO (1983) 20 Jahre Pengitoxin — eine Übersicht. Arzneimittelforsch (Drug Res) (in press)
Haustein KO, Pachaly C, Megges R, Franke P (1978a) Investigation into species-specific deacylation of penta-acetyl-gitoxin. Eur J Clin Pharmacol 14:425–430
Haustein KO, Pachaly C, Murawski D (1978b) Pharmacokinetic investigations with3H-penta-acetyl-gitoxin in volunteers and patients with respect to the occurrence of drug latentiation. Int J Clin Pharmacol 16:285–289
Hüller G, Haustein KO, Murawski D (1981) On the plasmaprotein binding of 16-acetyl-gitoxin. Int J Clin Pharmacol 19:200–202
Keller F, Blumenthal HP, Maertin K, Rietbrock N (1977) Overall pharmacokinetics during prolonged treatment of healthy volunteers with digoxin andβ-methyl-digoxin. Eur J Clin Pharmacol 12:387–392
Koup JR, Greenblatt DJ, Jusko WJ, Smith TW, Koch-Weser J (1975) Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm 3:181–192
Nelder JA, Mead R (1965) A simplex method for function minimizing. Computer J 7:308–313
Repke K, Megges R (1963) Die Entwicklung eines neuen Herzglykosidpräparates mit großer therapeutischer Breite (Pentaacetyl-gitoxin). Dtsch Gesundheitswes 18:1325–1333
Reuning RH, Sams RA, Notari RE (1973) Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effects, kinetics and apparent volume of distribution of digoxin. J Clin Pharmacol 13:127–135
Rietbrock N, Alken RG, Ebert W (1979) Vergleichende Untersuchung der absoluten Bioverfügbarkeit von vier oralen Digoxin-Präparaten. Arzneimittelforsch (Drug Res) 29:1742–1745
Schlesinger J (1973) Fit to experimental data with exponential functions using the fast Fourier transform. Nucl Instrum Methods 106:503–508
Storstein L (1976) Studies on digitalis. V. The influence of impaired renal function, hemodialysis, and drug interaction on serum protein binding of digitoxin and digoxin. Clin Pharmacol Ther 20:6–14
Vöhringer HF, Rietbrock N, Spurny P, Kuhlmann J, Hampl H, Baethke R (1976) Disposition of digoxin in renal failure. Clin Pharmacol Ther 19:387–395
Wagner JG, Popat KD, Das SK, Sakmar E, Movahhed H (1981) Evidence of nonlinearity in digoxin pharmacokinetics. J Pharmacokinet Biopharm 9:147–166
Weiler EW, Lach HJ (1980) Direct radioimmunoassay for the determination of 16-acetyl-gitoxin in serum. Clin Chim Acta 104:337–343
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haustein, K.O., Alken, R.G., Lach, H.J. et al. On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin. Eur J Clin Pharmacol 25, 369–373 (1983). https://doi.org/10.1007/BF01037950
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01037950